Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

NCT06704152 is registered in ClinicalTrials.gov with BlueSphere Bio, Inc as lead sponsor.

NCT NCT06704152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06704152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Lead sponsor
BlueSphere Bio, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
February 4, 2025
Completion date
September 8, 2026
Enrollment
2 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

all, recurrent, adult, aml, adult recurrent, mds